FIELD: medicine; pharmaceuticals.
SUBSTANCE: improved solubility of the pharmaceutical composition or dosage form containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or its salts, can be achieved by forming granules from said compound or salt thereof and enabling the presence of said granules together with a disintegrating agent.
EFFECT: obtaining a tetracyclic compound contained in a high dose.
21 cl, 8 dwg, 8 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2008 |
|
RU2470637C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING QUINOLINE DERIVATIVE | 2010 |
|
RU2548673C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PRODRUG OF HCV POLYMERASE INHIBITOR | 2010 |
|
RU2489153C2 |
| PHARMACEUTICAL SOLID PREPARATION CONTAINING BENZAZEPIN AND METHOD FOR PREPARING IT | 2008 |
|
RU2466717C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2639473C2 |
| IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITIONS | 1996 |
|
RU2181590C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| ORAL PREPARATION WITH SUSTAINED RELEASE | 2015 |
|
RU2696870C2 |
| COMPOSITION OF INHIBITOR OF 5α-REDUCTASE FOR ORAL ADMINISTRATION, METHOD OF ITS PREPARING AND USE | 1997 |
|
RU2154467C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
